NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

器官移植/組織移植及替代品

Organ and Tissue Transplantation and Alternatives

出版商 BCC Research 商品編碼 977431
出版日期 內容資訊 英文 207 Pages
訂單完成後即時交付
價格
器官移植/組織移植及替代品 Organ and Tissue Transplantation and Alternatives
出版日期: 2020年12月10日內容資訊: 英文 207 Pages
簡介

全球器官和組織移植及替代市場預計將從2020年的899億美元增長到2024年的1203億美元,從2019年到2024年的複合年增長率為7.4%。替代技術領域將從2020年的221億美元增長到2024年的308億美元,預計從2019年到2024年的複合年增長率為8.6%。從2019年到2024年,組織產品領域的複合年增長率預計將從2020年的384億美元增長到2024年的542億美元,增長8.9%。

本報告研究和分析了全球器官移植/組織移植和替代市場,並提供了有關市場概況,市場動態,市場細分,主要公司等的系統信息。

目錄

第1章簡介

第2章摘要和重點

第3章市場/技術背景

  • 治療費用
  • 實體器官的保存
  • 免疫抑制
  • 器官移植的替代方法
  • 器官移植/組織移植技術及其替代技術的趨勢
  • 3D組織組裝
  • 用於組織再生的納米技術
  • 創新:由小公司

第4章市場動態

  • 市場促進因素
  • 市場約束因素
  • 市場機會

第5章市場細分:按產品/設備分類

  • 器官移植/組織移植及其替代品的全球市場
  • 替代技術
  • 市場規模和預測
  • 心臟移植的替代方法
  • 手術
  • 機械
  • 完全替代人工心臟
  • 輔助人工心臟(VAD)
  • 設計生成
  • 骨科手術的替代方法
  • 紙巾產品
  • 市場規模和預測
  • 免疫抑製劑
  • 市場規模和預測
  • 固體器官保存液
  • 市場規模和預測
  • 正在開發的保存解決方案
  • 組織符合性檢查
  • 市場規模和預測

第6章市場細分:按地區

  • 器官移植/組織移植及其替代品的全球市場
  • 北美
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 意大利
  • 西班牙
  • 其他歐洲
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳大利亞/新西蘭
  • 其他亞太地區
  • 其他地區
  • 市場分析
  • 巴西
  • 南非
  • 其他國家

第7章COVID-19的影響

  • 簡介
  • 對腎臟移植計劃的影響
  • 對製藥公司的影響
  • 供體測試
  • 移植接受者中的COVID-19
  • 將接受者的感染風險降至最低
  • 未來展望

第8章供體過程概述

  • 簡介
  • 黑市捐助者
  • 移植過程
  • 美國實體器官移植的費用

第9章管制和贖回

  • 美國法規
  • 美國聯邦關於人體組織的法規
  • 美國的監管歷史
  • 美國以外的法規
  • 美國兌現
  • 器官獲取成本
  • 報銷住院費用
  • 兌換醫生服務
  • 在美國贖回免疫抑製劑
  • 在美國境外兌換
  • 歐盟國家的待遇

第10章競爭情況

  • 世界公司排名分析
  • 併購
  • 合同/開始/聯盟/夥伴關係

第11章公司簡介

  • ABIOMED INC.
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • CAREDX INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • MYLAN N.V.
  • NOVARTIS AG
  • PFIZER INC.
  • TRANSMEDICS INC.
  • VERTEX PHARMACEUTICALS INC.
  • XVIVO PERFUSION

第12章 附錄:縮寫

目錄
Product Code: HLC012G

Highlights:

The global organ and tissue transplantation and alternatives market should reach $120.3 billion by 2024 from $89.9 billion in 2020 at a compound annual growth rate (CAGR) of 7.4% for the forecast period of 2019 to 2024.

The alternative technologies segment of the global organ and tissue transplantation and alternatives market is expected to grow from $22.1 billion in 2020 to $30.8 billion in 2024 at a CAGR of 8.6% for the forecast period of 2019 to 2024.

The tissue products segment of the global organ and tissue transplantation and alternatives market is expected to grow from $38.4 billion in 2020 to $54.2 billion in 2024 at a CAGR of 8.9% for the forecast period of 2019 to 2024.

Report Scope:

This report offers forecasts, by product segment, from 2018 through 2024, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.

Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells and altered cancer cells.

The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.

Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques and pharmaceuticals are highlighted.

Profiles of leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies' available and emerging products.

An appendix featuring various terms and processes used in transplantation is provided at the end of the report.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, except for peripheral and umbilical cord blood as a source of stem cells.

By geography, the market has been segmented into the North America, Europe, Asia-Pacific, and Rest of the World regions. Detailed analysis of the market in major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2024.

Report Includes:

  • 26 data tables and 37 additional tables
  • An overview of the global organ and tissue transplantation and alternatives market
  • Estimation of the market size and analyses of market trends, with data from 2018 to 2019, estimates for 2020 and projection of CAGR through 2024
  • Details about organ and tissue transplantation and alternatives, their pathophysiology and affects, and major advancement and latest trends
  • A look at the regulatory scenarios and initiatives by government organization
  • Analysis of current and future market dynamics and identification of key drivers, restraints and opportunities such as increasing incidence of organ donations, improved awareness about organ donations, side effects of organ and tissue transplantation and antibiotic resistance infections
  • Coverage of emerging procedures and products in development and discussion on prevalence of major chronic diseases which initiates organ damage or donation
  • Discussion on the role of the organ procurement organization and information on transplantation process and preparation and coverage of issues like black market donors
  • Impact analysis of COVID-19 on organ and tissue transplantation and alternatives market
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Company profiles of major players of the industry, including Abiomed Inc., Bayer AG, F. Hoffmann-La Roche & Co., Johnson & Johnson, Novartis AG, Pfizer Inc. and XVIVO Perfusion

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Cost of Care
  • Solid Organ Preservation
  • Immunosuppression
  • Organ Transplantation Alternatives
  • Trends in Organ and Tissue Transplantation Techniques and Their Alternatives
  • 3D Tissue Assembly
  • Nanotechnology for Tissue Regeneration
  • Innovation by Small Firms

Chapter 4 Market Dynamics

  • Market Drivers
  • Increasing Epidemiology of Different Diseases Influencing Organ Transplantations
  • Rise in the Geriatric Population
  • Rising Awareness of Importance of Organ and Tissue Donation
  • New Therapeutic Pathways for Organ Transplantation and Their Alternatives
  • Market Restraints
  • Challenges in Human Leukocyte Antigen (HLA) Sequencing
  • Demand and Supply Gap
  • Market Opportunities
  • Growing Economic Benefits of Organ and Tissue Transplants
  • Improvement in Healthcare Infrastructure

Chapter 5 Market Breakdown by Product & Devices

  • Global Market for Organ and Tissue Transplantation and Alternatives
  • Alternative Technologies
  • Market Size and Forecast
  • Alternatives to Heart Transplantation
  • Surgical
  • Mechanical
  • Total Artificial Heart
  • Ventricular Assist Devices (VADs)
  • Generations of Designs
  • Orthopedic Alternatives
  • Tissue Products
  • Market Size and Forecast
  • Immunosuppressants
  • Market Size and Forecast
  • Solid Organ Preservation Solutions
  • Market Size and Forecast
  • Preservation Solutions in Development
  • Tissue Typing
  • Market Size and Forecast

Chapter 6 Market Breakdown by Region

  • Global Market for Organ and Tissue Transplantation and Alternatives by Region
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia and New Zealand
  • Rest of Asia-Pacific
  • Rest of the World
  • Market Analysis
  • Brazil
  • South Africa
  • Rest of the World Countries

Chapter 7 Impact of COVID-19

  • Introduction
  • Impact on Kidney Transplant Program
  • Impact on Pharmaceutical Companies
  • Donor Testing
  • COVID-19 in Transplant Recipients
  • Minimizing Infection Risk in Recipients
  • Future Perspectives

Chapter 8 Overview of Donation Process

  • Introduction
  • Black Market Donors
  • The Transplantation Process
  • Cost of Solid Organ Transplantation in the U.S.

Chapter 9 Regulations & Reimbursement

  • Regulations in the U.S.
  • U.S. Federal Regulation of Human Tissue
  • History of Regulation in the U.S.
  • Regulations Outside the U.S.
  • Reimbursement in the U.S.
  • Organ Acquisition Costs
  • Reimbursement for Hospital Costs
  • Reimbursement for Physician Services
  • Reimbursement for Immunosuppressants in the U.S.
  • Reimbursement Outside the U.S.
  • Treatment in EU Countries

Chapter 10 Competitive Landscape

  • Global Company Ranking Analysis
  • Mergers and Acquisitions
  • Agreements, Launches, Collaborations, and Partnerships

Chapter 11 Company Profiles

  • ABIOMED INC.
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • CAREDX INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • MYLAN N.V.
  • NOVARTIS AG
  • PFIZER INC.
  • TRANSMEDICS INC.
  • VERTEX PHARMACEUTICALS INC.
  • XVIVO PERFUSION

Chapter 12 Appendix: Acronyms

List of Tables

  • Summary Table A : Global Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
  • Summary Table B : Global Market for Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
  • Table 1 : MiMedx: Patent Portfolio
  • Table 2 : Product Launches in Transplant Diagnostics, 2012-2016
  • Table 3 : Global Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
  • Table 4 : Global Market for Alternative Technologies in Organ and Tissue Transplantation and Alternatives, Through 2024
  • Table 5 : Selected Global Commercial Opportunities for New Orthopedic Devices in the Future
  • Table 6 : Indications for Bioartificial Liver Transplantation
  • Table 7 : Global Market for Alternative Technologies in the Organ and Tissue Transplantation and Alternatives Market, by Region, Through 2024
  • Table 8 : Global Market for Tissue Products in the Organ and Tissue Transplantation and Alternatives Market, Through 2024
  • Table 9 : Cartilage and Soft Tissue Biologics and Biomaterials
  • Table 10 : Global Market of Tissue Products in Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
  • Table 11 : Therapeutic Effects of Immunosuppressants
  • Table 12 : Global Market for Immunosuppressants in the Organ and Tissue Transplantation and Alternatives Market, Through 2024
  • Table 13 : Immunosuppressants, by Drug Class, Generic Name, Brand Name, and Manufacturer
  • Table 14 : Global Market of Immunosuppressants in the Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
  • Table 15 : Cold Ischemia Time for Transplanted Organs
  • Table 16 : Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, Through 2024
  • Table 17 : Optimal Preservation Solution Design
  • Table 18 : Major Organ Preservation Solutions
  • Table 19 : Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
  • Table 20 : Tissue Typing Technologies
  • Table 21 : Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, Through 2024
  • Table 22 : Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
  • Table 23 : Global Market for Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
  • Table 24 : North American Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
  • Table 25 : North American Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
  • Table 26 : European Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
  • Table 27 : European Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
  • Table 28 : Transplant Numbers in Germany, 2013-2019
  • Table 29 : Statistics for Cost of Bone Damage Repair and Related Disorders in Europe
  • Table 30 : Asia-Pacific Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
  • Table 31 : Asia-Pacific Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
  • Table 32 : Types of Organ Rejection After Transplant Procedures
  • Table 33 : Organ Transplantation Rates in Southeast Asian Countries, 2011-2014
  • Table 34 : Rest of the World Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
  • Table 35 : Registered Liver Transplantations (LT)/Kidney Transplantation in Middle East Countries, 2017
  • Table 36 : Rest of the World Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
  • Table 37 : Communicable and Noncommunicable Diseases Leading to Mortality in Brazil, 2018
  • Table 38 : Number of Organ Transplant Procedures in Brazil, by Type of Organ, 2015
  • Table 39 : Number of Organ Transplant Procedures in Turkey, by Type of Organ, 2019-2020
  • Table 40 : Pharmaceutical Company Efforts to Tackle COVID-19
  • Table 41 : U.S. Organ/Tissue Transplants: Total Estimated Transplants and Estimated Billed Charges, 2019
  • Table 42 : Immunosuppressive Drugs Currently Covered, by Medicare*
  • Table 43 : Overview of Medicare Immunosuppressive Drug Coverage
  • Table 44 : Selected Transplant Industry Acquisitions, 2010-Early 2015
  • Table 45 : Abiomed Inc: Product Portfolio
  • Table 46 : AbbVie: Product Portfolio
  • Table 47 : Amgen Inc.: Product Portfolio
  • Table 48 : AstraZeneca: Product Portfolio
  • Table 49 : Bayer AG: Product Portfolio
  • Table 50 : Bristol-Myers Squibb: Product Portfolio
  • Table 51 : CareDx Inc.: Product Portfolio
  • Table 52 : F. Hoffmann-La Roche & Co.: Product Portfolio
  • Table 53 : Johnson & Johnson: Immunosuppressants Product Portfolio
  • Table 54 : Mylan N.V.: Product Portfolio
  • Table 55 : Novartis AG: Product Portfolio
  • Table 56 : Pfizer Inc.: Product Portfolio
  • Table 57 : Pfizer Inc.: Pipeline Product Portfolio
  • Table 58 : Transmedics Inc.: Product Portfolio
  • Table 59 : Vertex Pharmaceuticals Inc.: Product Portfolio
  • Table 60 : XVIVO Perfusion: Product Portfolio
  • Table 61 : Acronyms Used in This Report

List of Figures

  • Summary Figure A : Global Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2018-2024
  • Summary Figure B : Global Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
  • Summary Figure C : Global Market Shares for Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
  • Summary Figure D : Global Market Shares for Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
  • Summary Figure E : Global Market Shares for Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
  • Figure 1 : Nanotechnology and Tissue Regeneration
  • Figure 2 : Number of Elderly (≥ 65 Years) Receiving Kidney Transplantation in the U.S., 2014-2018
  • Figure 3 : Number of Diabetes Patients Globally (20 to 79 Years of Age), 2000-2045
  • Figure 4 : Waiting List for Organs in the U.S., by Type of Organ, September 2020
  • Figure 5 : Number of Kidney Transplants, by Country, 2015
  • Figure 6 : Patients on Waiting List vs. Transplant Performed in the U.S., by Organ, 2019
  • Figure 7 : Global Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
  • Figure 8 : Global Market for Alternative Technologies in Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 9 : Global Market Shares of Alternative Technologies in Organ and Tissue Transplantation and Alternatives, 2019
  • Figure 10 : Global Market Shares of Orthopedic Alternatives in Organ and Tissue Transplantation and Alternatives, 2019
  • Figure 11 : Global Market for Alternative Technologies in the Organ and Tissue Transplantation and Alternatives Market, by Region, 2018-2024
  • Figure 12 : Global Market for Tissue Products in the Organ and Tissue Transplantation and Alternatives Market, 2018-2024
  • Figure 13 : Global Market Shares for Tissue Products in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 14 : Global Market Shares for Peripheral Blood Stem Cells, Cord Blood, Bone Marrow in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 15 : Global Market Shares for Orthobiologics (Bone Allografts, Machined Bone, DBM) in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 16 : Global Market of Tissue Products in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
  • Figure 17 : Global Market for Immunosuppressants in the Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 18 : Global Market Shares for Immunosuppressants in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 19 : Global Market Shares for Calcineurin Inhibitors in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 20 : Global Market Shares for Anti-proliferative Agents in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 21 : Global Market Shares for m-TOR Inhibitors in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 22 : Global Market Shares for Polyclonal Antibodies in the Organ and Tissue Transplantation and Alternatives Market, 2019
  • Figure 23 : Global Market of Immunosuppressants in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
  • Figure 24 : Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 25 : Global Market Shares for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, 2019
  • Figure 26 : Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
  • Figure 27 : Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 28 : Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
  • Figure 29 : Global Market Shares of Organ and Tissue Transplantation and Alternatives, by Region, 2019
  • Figure 30 : North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
  • Figure 31 : North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Devices, 2019
  • Figure 32 : North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
  • Figure 33 : North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
  • Figure 34 : North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
  • Figure 35 : North American Market Shares for Organ and Tissue Transplantation and Alternatives, by Country, 2019
  • Figure 36 : United States Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 37 : Canadian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 38 : Mexican Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 39 : European Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
  • Figure 40 : European Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
  • Figure 41 : European Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
  • Figure 42 : European Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
  • Figure 43 : European Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
  • Figure 44 : European Market Shares of Organ and Tissue Transplantation and Alternatives, by Country, 2019
  • Figure 45 : German Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 46 : French Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 47 : U.K. Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 48 : Italian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 49 : Spainish Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 50 : Rest of Europe Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 51 : Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
  • Figure 52 : Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
  • Figure 53 : Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
  • Figure 54 : Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
  • Figure 55 : Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
  • Figure 56 : Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Country, 2019
  • Figure 57 : Japanese Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 58 : Chinese Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 59 : Indian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 60 : Australia and New Zealand's Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 61 : Number of Organ Donations in Australia, by Type of Donor, 2015
  • Figure 62 : Rest of Asia-Pacific Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 63 : Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Products & Devices, 2019
  • Figure 64 : Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
  • Figure 65 : Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
  • Figure 66 : Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
  • Figure 67 : Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
  • Figure 68 : Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Country, 2019
  • Figure 69 : Brazilian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 70 : South African Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 71 : Rest of the World Countries Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
  • Figure 72 : Steep Reduction in Organ Transplantation Seen During COVID-19
  • Figure 73 : Global Market Ranking in the Organ and Tissue Transplantation and Alternatives Market, by Pharmaceutical Company, 2019
  • Figure 74 : Global Market Ranking of Organ and Tissue Transplantation and Alternatives, by Diagnostic and Alternatives in the Organ Manufacturing Industry, 2019
  • Figure 75 : Abiomed Inc.: Annual Revenue, 2016-2020
  • Figure 76 : Abiomed Inc.: Revenue Shares for R&D, by Impella Devices, 2016-2020
  • Figure 77 : AbbVie: Annual Revenue, 2016-2019
  • Figure 78 : AbbVie: Revenue Shares, by Region/Country, 2019
  • Figure 79 : AbbVie: Revenue Shares, by Business Unit, 2019
  • Figure 80 : Amgen Inc.: Annual Revenue, 2016-2019
  • Figure 81 : Amgen Inc.: Revenue Shares, by Region/Country, 2019
  • Figure 82 : Amgen Inc.: Revenue Shares, by Products, 2019
  • Figure 83 : AstraZeneca: Annual Revenue, 2016-2019
  • Figure 84 : AstraZeneca: Revenue Shares, by Region/Country, 2019
  • Figure 85 : AstraZeneca: Revenue Shares, by Business Unit, 2019
  • Figure 86 : Bayer AG: Annual Revenue, 2016-2019
  • Figure 87 : Bayer AG: Revenue Shares, by Region, 2019
  • Figure 88 : Bayer AG: Revenue Shares, by Business Unit, 2019
  • Figure 89 : Bristol-Myers Squibb: Annual Revenue, 2016-2019
  • Figure 90 : Bristol-Myers Squibb: Revenue Shares, by Region/Country, 2019
  • Figure 91 : Bristol-Myers Squibb: Revenue Shares, by Brands, 2019
  • Figure 92 : CareDx Inc.: Annual Revenue, 2016-2019
  • Figure 93 : CareDx Inc.: Revenue Shares in Pharmaceutical Segment, by Region/Country, 2019
  • Figure 94 : CareDx Inc.: Revenue Shares, by Business Segment, 2019
  • Figure 95 : F. Hoffmann-La Roche & Co.: Annual Revenue, 2016-2019
  • Figure 96 : F. Hoffmann-La Roche & Co.: Revenue Shares in Pharmaceutical Segment, by Region/Country, 2019
  • Figure 97 : F. Hoffmann-La Roche & Co.: Revenue Shares, by Business Segment, 2019
  • Figure 98 : Johnson & Johnson: Annual Revenue, 2016-2019
  • Figure 99 : Johnson & Johnson: Revenue Shares, by Region/Country, 2019
  • Figure 100 : Johnson & Johnson: Revenue Shares, by Business Unit, 2019
  • Figure 101 : Mylan N.V.: Annual Revenue, 2016-2019
  • Figure 102 : Mylan N.V.: Revenue Shares, by Region, 2019
  • Figure 103 : Mylan N.V.: Revenue Shares, by Business Unit, 2019
  • Figure 104 : Novartis AG.: Annual Revenue, 2015-2019
  • Figure 105 : Novartis AG: Revenue Shares, by Region/Country, 2019
  • Figure 106 : Novartis AG: Revenue Shares, by Business Segment, 2019
  • Figure 107 : Pfizer Inc.: Annual Revenue, 2016-2019
  • Figure 108 : Pfizer Inc.: Revenue Shares, by Region/Country, 2019
  • Figure 109 : Pfizer Inc.: Revenue Shares, by Business Segment, 2019
  • Figure 110 : Transmedics Inc.: Annual Revenue, 2018 and 2019
  • Figure 111 : Transmedics Inc.: Revenue Shares, by OCS Product, 2019
  • Figure 112 : Transmedics Inc.: Revenue Shares, by Region/Country, 2019
  • Figure 113 : Vertex Pharmaceuticals Inc.: Annual Revenue, 2016-2019
  • Figure 114 : Vertex Pharmaceuticals Inc.: Research and Development Expense, 2017-2019
  • Figure 115 : Vertex Pharmaceuticals Inc.: Revenue Shares, by Business Segment, 2019
  • Figure 116 : XVIVO Perfusion: Annual Revenue, 2018 and 2019
  • Figure 117 : XVIVO Perfusion: Revenue Shares, by Region, 2019